The mitigation of morbidity risk in patients with COVID-19 infection in the progression of acute respiratory distress syndrome (ARDS) related to severe respiratory tract damage with the high blood level of inflammatory markers as Cytokines IL-6 is an essential goal of contemporary treatment these patients in ICU environment. The Plasma Exchange therapy (TPE) with continuous hemofiltration (CHF) reduced level IL-6 and other cytokines in patients with different critical pathologies as fulminant liver damage, autoimmune inflammation, neurological and infectious diseases.
The severe damage of the lung tissue can result in acute respiratory distress syndrome (ARDS), which can further precipitate septic shock. The possible high mortality rate of COVID-19 can be connected to the increasing of Th17 cells activity mainly stimulated by IL-6 and IL-23. Removing IL-6 and IL-23 can improve the COVID-19th outcomes.
I hope this article will help in the reduction of COVID-19 mortality rate.Dr. Sergey Zhuplatov, MD, PhD
J Anest & Inten Care Med.
J Anest & Inten Care Med 10(5): JAICM.MS.ID.555798 (2020). DOI:10.19080/JAICM.2020.10.555798.